Tan Jun-Lan, Yi Jian, Cao Xian-Ya, Wang Fei-Ying, Xie Si-Lin, Zhou Ling-Ling, Qin Li, Dai Ai-Guo
Department of Respiratory Diseases, School of Medicine, Hunan University of Chinese Medicine, Changsha 410208, Hunan, China; Hunan Provincial Key Laboratory of Vascular Biology and Translational Medicine, Changsha 410208, Hunan, China.
The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410021, Hunan, China.
Biomed Pharmacother. 2023 Feb;158:114177. doi: 10.1016/j.biopha.2022.114177. Epub 2023 Jan 3.
Evidence is mounting that abnormal vascular remodeling leads to many cardiovascular diseases (CVDs). This suggests that vascular remodeling can be a crucial target for the prevention and treatment of CVDs. Recently, celastrol, an active ingredient of the broadly used Chinese herb Tripterygium wilfordii Hook F, has attracted extensive interest for its proven potential to improve vascular remodeling. Substantial evidence has shown that celastrol improves vascular remodeling by ameliorating inflammation, hyperproliferation, and migration of vascular smooth muscle cells, vascular calcification, endothelial dysfunction, extracellular matrix remodeling, and angiogenesis. Moreover, numerous reports have proven the positive effects of celastrol and its therapeutic promise in treating vascular remodeling diseases such as hypertension, atherosclerosis, and pulmonary artery hypertension. The present review summarizes and discusses the molecular mechanism of celastrol regulating vascular remodeling and provides preclinical proof for future clinical applications of celastrol.
越来越多的证据表明，异常的血管重塑会导致许多心血管疾病（CVD）。这表明血管重塑可能是预防和治疗CVD的关键靶点。最近，雷公藤红素是广泛使用的中草药雷公藤的活性成分，因其已被证实的改善血管重塑的潜力而引起了广泛关注。大量证据表明，雷公藤红素通过改善血管平滑肌细胞的炎症、过度增殖和迁移、血管钙化、内皮功能障碍、细胞外基质重塑和血管生成来改善血管重塑。此外，许多报告已经证实了雷公藤红素的积极作用及其在治疗血管重塑疾病如高血压、动脉粥样硬化和肺动脉高压方面的治疗前景。本综述总结并讨论了雷公藤红素调节血管重塑的分子机制，并为雷公藤红素未来的临床应用提供临床前证据。
